Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256954 | 0.92 | AVPR2 (0.82) | AVPR2AVPR1A | |
| SCHEMBL15206236 | 0.91 | AVPR2 (0.85) | AVPR2AVPR1A | |
| SCHEMBL10217646 | 0.91 | AVPR2 (0.77) | AVPR2AVPR1A | |
| SCHEMBL10217657 | 0.90 | AVPR2 (0.75) | AVPR2AVPR1A | |
| SCHEMBL412722 | 0.89 | AVPR2 (0.79) | AVPR2AVPR1A | |
| SCHEMBL408829 | 0.89 | AVPR2 (0.81) | AVPR2AVPR1A | |
| SCHEMBL256836 | 0.88 | AVPR2 (0.81) | AVPR2AVPR1A | |
| SCHEMBL168160 | 0.88 | AVPR2 (0.81) | AVPR2AVPR1A | |
| SCHEMBL3446936 | 0.88 | AVPR2 (0.79) | AVPR2AVPR1A | |
| SCHEMBL257007 | 0.88 | AVPR2 (1.00) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9180120-B2 | Substituted N-phenethyltriazoloneacetamides and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| EP-2619188-B1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER IP GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-20130225646-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2012028644-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225646-A1 | SUBSTITUTED N-PHENETHYLTRIAZOLONEACETAMIDES AND USE THEREOF | TNNT2, TNNI3, PNMT | AVPR2 2657/4885AVPR1A 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.